Optimal Patient Management With SC Amivantamab Plus Lazertinib in Frontline EGFR+ NSCLC

Misako Nagasaka, MD, PhD, discusses optimizing patient management when administering frontline SC amivantamab plus lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer. She describes how the majority of adverse events (AEs) with the SC regimen in the PALOMA-2 trial occurred during first 4 months of treatment. According to Nagasaka, this highlights the importance of early patient counseling regarding expectations and reporting of AEs when starting the SC regimen.